OABI · NASDAQ
OmniAb, Inc.
$4.89 -0.35 (-6.68%)
Company overview
OmniAb, Inc. is a biotechnology company that provides therapeutic antibody discovery technologies in the United States. Its discovery platform gives industry partners access to diverse antibody repertoires and screening technologies for discovering next-generation therapeutics. The OmniAb platform leverages proprietary transgenic animals—including OmniRat, OmniChicken, and OmniMouse—that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic and OmniClic address industry needs for bispecific antibody applications through a common light chain approach, while OmniTaur offers unique structural attributes of cow antibodies for complex targets. Founded in 2012, OmniAb is headquartered in Emeryville, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $711M
- Employees
- 114
- Headquarters
- EmeryVille, CA
- Website
- omniab.com
- CEO
- Matthew W. Foehr
- Listed
- September 30, 2021
- P/E
- -10.70
- Dividend yield
- 0.00%
Company financials
- Revenue
- $28.9M
- Gross profit
- $10.2M
- Operating income
- -$57.9M
- EBITDA
- -$35.1M
- Net income
- -$54.3M
- EPS
- -$0.46
- Total assets
- $294M
- Total debt
- $19.7M
- Gross margin
- 35.45%
- Net margin
- -187.74%
- Earnings yield
- -9.35%
No geographic segmentation.
Showing FY 2025
OABI
1D
NASDAQ
O5.35H5.41L5.14C5.23-0.05 (-0.95%)Vol1.68M